Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2020 / N 2

Применение ингибиторов SGLT-2 у пациентов с сердечной недостаточностью: обзор клинических исследований
Д.В. Рябова, А.Д. Эрлих, О.А. Кисляк

Список литературы

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart (British Cardiac Society) 2007 Sep;93(9):1137-46.
2. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation. Heart Failure 2013 May;6(3):606-19.
3. Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, Witteman JCM, Stricker BHC. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. European Heart Journal 2004 Sep;25(18):1614-9.
4. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Current Heart Fail Reports 2013 Dec;10(4):401-10.
5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JCF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2016 Jul;37(27):2129-200.
6. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational research programme: regional differences and 1-year follow-up results of the Heart Failure Pilot survey (ESC-HF Pilot). European Journal of Heart Failure 2013 Jul;15(7):808-17.
7. Chao EC. SGLT-2 inhibitors: a new mechanism for glycemic control. Clinical Diabetes 2014 Jan;32(1):4-11.
8. Madaan T, Akhtar M, Najmi AK. Sodium glucose co-transporter 2 (SGLT2) inhibitors: current status and future perspective. European Journal of Pharmaceutical Sciences 2016 Oct;93:244-52.
9. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine 2015 Nov;373(22):2117-28.
10. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. The New England Journal of Medicine 2017 Aug;377(7):644-57.
11. Perkovic М, Jardine MG, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. The New England Journal of Medicine 2019 Jun;380(24):2295-306.
12. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine 2019 Jan;380(4):347-57.
13. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet 2019 Jan;393(10166):31-9.
14. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 2017 Oct;136(17):1643-58.
15. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016 Sep;134(10):752-72.
16. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012;5:313-27.
17. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75(1):33-59.
18. Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiology 2017 Sep;2(9):1025-9.
19. Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. Journal of the American Heart Association 2019 Oct;8(20):e013389.
20. Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovascular Diabetology 2018 May;17(1):73.
21. Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovascular Diabetology 2019 Jun;18(1):76.
22. Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovascular Diabetology 2018 Oct;17(1):132.
23. Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, Toda H, Namba S, Nakamura Y, Akagi S, Sakuragi S, Minagawa T, Kawai Y, Nakamura K, Ito H. Drug effect of luseogliflozin and voglibose on heart failure with preserved ejection fraction in diabetic patients: a multicenter randomized-controlled trial. Presentation at ESC Congress 2019 together with World Congress of Cardiology; Paris, France; 2019 Aug 31–Sep 04. Abstract: 1407.
24. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca M, Ruff CT, Desai AS, Goto S, Johansson A, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019 May;139(22):2528-36.
25. Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation 2018 Jul;138(5):458-68.
26. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Trial Investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. European Heart Journal 2016 May;37(19):1526-34.
27. Nassif ME, Windsor SL, Tang BSF, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, Drazner MH, Fong MW, Givertz MM, Gordon RA, Jermyn R, Katz SD, Lamba S, Lanfear DE, LaRue SJ, Lindenfeld JA, Malone M, Margulies K, Mentz RJ, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation 2019;140(18):1463-76.
28. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK., de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. The New England Journal of Medicine 2019 Nov;381(21):1995-2008.
29. Docherty KF, Jhund PF, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjöstrand M, Langkilde AM, Desai AS, Diez M, Howlett JG, Katova T, Ljungman CEA, O’Meara E, Petrie MC, Schou M, Verma S, Vinh PN, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal 2020 Jul;41(25):2379-92.
30. Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Ponikowski P, Sabatine MS, DeMets DL, Dutkiewicz-Piasecka M, Bengtsson O, M. Sjöstrand, Langkilde AM, Jhund PS, McMurray JJV. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation 2020;141:100-11.
31. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, van Eck JWM, Heerspink HJL, Voors AA. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). European Journal of Heart Failure 2020 Apr;22(4):713-22.
32. Kambara T, Shibata R, Osanai H, Nakashima Y, Asano H, Murohara T, Ajioka M. Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure. Therapeutic Advances in Cardiovascular Disease 2019 Jan-Dec;13:1753944719894509.
33. Nakagaito M, Joho S, Ushijima R, Nakamura M, Hirai T, Kinugawa K. Short-term effects of dapagliflozin versus canagliflozin on acute decompensated heart failure in patients with type 2 diabetes. Presentation at ESC Congress 2019 together with World Congress of Cardiology; Paris, France; 2019 Aug 31–Sep 04. Abstract: 4328.
34. Nakagaito M, Joho S, Ushijima R, Nakamura M, Hirai T, Kinugawa K. Comparison of canagliflozin, dapagliflozin and empagliflozin added to heart failure treatment in decompensated heart failure patients with type 2 diabetes mellitus. Circulation Reports 2019;1(10):405-13.
35. Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. European Journal of Heart Failure 2017 Nov;19(11):1390-400.
36. NIH. U.S. National Library of Medicine. ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt failure with Reduced ejection fraction (EMPEROR-Reduced). Available from: https://clinicaltrials.gov/ct2/show/NCT03057977 Accessed 2020 Oct 23.
37. Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George I, Brueckmann M, Zannad F, Packer M; EMPEROR‐Preserved Trial Committees and Investigators. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial. European Journal of Heart Failure 2019 Oct;21(10):1279-87.
38. NIH. U.S. National Library of Medicine. ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt failure with Preserved ejection fraction (EMPEROR-Preserved). Available from: https://clinicaltrials.gov/ct2/show/NCT03057951 Accessed 2020 Oct 23.
39. Jensen О, Omar M, Kistorp C, Poulsen MK, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Fosbøl E, Bruun NE, Videbæk L, Frederiksen PH, Møller JE, Schou M. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). Trials 2019 Jun;20(1):374.
40. NIH. U.S. National Library of Medicine. ClinicalTrials.gov. Efficacy and safety of dapagliflozin in acute heart failure (DICTATE-AHF). Available from: https://clinicaltrials.gov/ct2/show/record/NCT04298229 Accessed 2020 Oct 23.
41. NIH. U.S. National Library of Medicine. ClinicalTrials.gov. Dapagliflozin Evaluation to improve the LIVEs of patients with pReserved ejection fraction heart failure (DELIVER). Available from: https://clinicaltrials.gov/ct2/show/NCT03619213?term=dapagliflozin&cond=Heart+Failure+with+Preserved+Ejection+Fraction&rank=1#wrapper Accessed 2020 Oct 23.

References

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart (British Cardiac Society) 2007 Sep;93(9):1137-46.
2. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation. Heart Failure 2013 May;6(3):606-19.
3. Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, Witteman JCM, Stricker BHC. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. European Heart Journal 2004 Sep;25(18):1614-9.
4. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Current Heart Fail Reports 2013 Dec;10(4):401-10.
5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JCF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2016 Jul;37(27):2129-200.
6. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational research programme: regional differences and 1-year follow-up results of the Heart Failure Pilot survey (ESC-HF Pilot). European Journal of Heart Failure 2013 Jul;15(7):808-17.
7. Chao EC. SGLT-2 inhibitors: a new mechanism for glycemic control. Clinical Diabetes 2014 Jan;32(1):4-11.
8. Madaan T, Akhtar M, Najmi AK. Sodium glucose co-transporter 2 (SGLT2) inhibitors: current status and future perspective. European Journal of Pharmaceutical Sciences 2016 Oct;93:244-52.
9. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine 2015 Nov;373(22):2117-28.
10. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. The New England Journal of Medicine 2017 Aug;377(7):644-57.
11. Perkovic М, Jardine MG, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. The New England Journal of Medicine 2019 Jun;380(24):2295-306.
12. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine 2019 Jan;380(4):347-57.
13. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet 2019 Jan;393(10166):31-9.
14. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 2017 Oct;136(17):1643-58.
15. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016 Sep;134(10):752-72.
16. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012;5:313-27.
17. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75(1):33-59.
18. Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiology 2017 Sep;2(9):1025-9.
19. Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. Journal of the American Heart Association 2019 Oct;8(20):e013389.
20. Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovascular Diabetology 2018 May;17(1):73.
21. Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovascular Diabetology 2019 Jun;18(1):76.
22. Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovascular Diabetology 2018 Oct;17(1):132.
23. Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, Toda H, Namba S, Nakamura Y, Akagi S, Sakuragi S, Minagawa T, Kawai Y, Nakamura K, Ito H. Drug effect of luseogliflozin and voglibose on heart failure with preserved ejection fraction in diabetic patients: a multicenter randomized-controlled trial. Presentation at ESC Congress 2019 together with World Congress of Cardiology; Paris, France; 2019 Aug 31–Sep 04. Abstract: 1407.
24. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca M, Ruff CT, Desai AS, Goto S, Johansson A, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019 May;139(22):2528-36.
25. Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation 2018 Jul;138(5):458-68.
26. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE the EMPA-REG OUTCOME Trial Investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. European Heart Journal 2016 May;37(19):1526-34.
27. Nassif ME, Windsor SL, Tang BSF, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, Drazner MH, Fong MW, Givertz MM, Gordon RA, Jermyn R, Katz SD, Lamba S, Lanfear DE, LaRue SJ, Lindenfeld JA, Malone M, Margulies K, Mentz RJ, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation 2019;140(18):1463-76.
28. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK., de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. The New England Journal of Medicine 2019 Nov;381(21):1995-2008.
29. Docherty KF, Jhund PF, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjöstrand M, Langkilde AM, Desai AS, Diez M, Howlett JG, Katova T, Ljungman CEA, O’Meara E, Petrie MC, Schou M, Verma S, Vinh PN, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal 2020 Jul;41(25):2379-92.
30. Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Ponikowski P, Sabatine MS, DeMets DL, Dutkiewicz-Piasecka M, Bengtsson O, M. Sjöstrand, Langkilde AM, Jhund PS, McMurray JJV. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation 2020;141:100-11.
31. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, van Eck JWM, Heerspink HJL, Voors AA. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). European Journal of Heart Failure 2020 Apr;22(4):713-22.
32. Kambara T, Shibata R, Osanai H, Nakashima Y, Asano H, Murohara T, Ajioka M. Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure. Therapeutic Advances in Cardiovascular Disease 2019 Jan-Dec;13:1753944719894509.
33. Nakagaito M, Joho S, Ushijima R, Nakamura M, Hirai T, Kinugawa K. Short-term effects of dapagliflozin versus canagliflozin on acute decompensated heart failure in patients with type 2 diabetes. Presentation at ESC Congress 2019 together with World Congress of Cardiology; Paris, France; 2019 Aug 31–Sep 04. Abstract: 4328.
34. Nakagaito M, Joho S, Ushijima R, Nakamura M, Hirai T, Kinugawa K. Comparison of canagliflozin, dapagliflozin and empagliflozin added to heart failure treatment in decompensated heart failure patients with type 2 diabetes mellitus. Circulation Reports 2019;1(10):405-13.
35. Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. European Journal of Heart Failure 2017 Nov;19(11):1390-400.
36. NIH. U.S. National Library of Medicine. ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt failure with Reduced ejection fraction (EMPEROR-Reduced). Available from: https://clinicaltrials.gov/ct2/show/NCT03057977 Accessed 2020 Oct 23.
37. Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George I, Brueckmann M, Zannad F, Packer M; EMPEROR‐Preserved Trial Committees and Investigators. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial. European Journal of Heart Failure 2019 Oct;21(10):1279-87.
38. NIH. U.S. National Library of Medicine. ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt failure with Preserved ejection fraction (EMPEROR-Preserved). Available from: https://clinicaltrials.gov/ct2/show/NCT03057951 Accessed 2020 Oct 23.
39. Jensen О, Omar M, Kistorp C, Poulsen MK, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Fosbøl E, Bruun NE, Videbæk L, Frederiksen PH, Møller JE, Schou M. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). Trials 2019 Jun;20(1):374.
40. NIH. U.S. National Library of Medicine. ClinicalTrials.gov. Efficacy and safety of dapagliflozin in acute heart failure (DICTATE-AHF). Available from: https://clinicaltrials.gov/ct2/show/record/NCT04298229 Accessed 2020 Oct 23.
41. NIH. U.S. National Library of Medicine. ClinicalTrials.gov. Dapagliflozin Evaluation to improve the LIVEs of patients with pReserved ejection fraction heart failure (DELIVER). Available from: https://clinicaltrials.gov/ct2/show/NCT03619213?term=dapagliflozin&cond=Heart+Failure+with+Preserved+Ejection+Fraction&rank=1#wrapper Accessed 2020 Oct 23.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]